Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis

Lisa J. Ewans 1,2,3✉, Andre E. Minoche 1,2, Deborah Schofield 6, Rupendra Shrestha 5, Clare Puttick 7, Ying Zhu 5,6, Alexander Drew 1, Velimir Gayevsky 2, George Elakis 6, Corrina Walsh 6, Lesley C. Ades 7,8, Alison Colley 9, Carolyn Ellaway 7,8, Carey-Anne Evans 6,10, Mary-Louise Freckmann 11, Linda Goodwin 12, Anna Hackett 8, Benjamin Kamien 13, Edwin P. Kirk 10,14, Michelle Lipke 3,15, David Mowat 3,14, Elizabeth Palmer 3,5,14, Sulekha Rajagopalan 9, Anne Ronan 13, Rani Sachdev 3,14, William Stevenson 16,17, Anne Turner 3,14, Meredith Wilson 7,8, Lisa Worgan 9, Marie-Christine Morel-Kopp 16,17, Michael Field 8,5, Michael F. Buckley 6, Mark J. Cowley 1,2, Marcel E. Dinger 2,18,19✉ and Tony Roscioli 3,6,10,19✉

© Crown 2022

Whole genome sequencing (WGS) improves Mendelian disorder diagnosis over whole exome sequencing (WES); however, additional diagnostic yields and costs remain undefined. We investigated differences between diagnostic and cost outcomes of WGS and WES in a cohort with suspected Mendelian disorders. WGS was performed in 38 WES-negative families derived from a 64 family Mendelian cohort that previously underwent WES. For new WGS diagnoses, contemporary WES reanalysis determined whether variants were diagnosable by original WES or unique to WGS. Diagnostic rates were estimated for WES and WGS to simulate outcomes if both had been applied to the 64 families. Diagnostic costs were calculated for various genomic testing scenarios. WGS diagnosed 34% (13/38) of WES-negative families. However, contemporary WES reanalysis on average 2 years later would have diagnosed 18% (7/38 families) resulting in a WGS-specific diagnostic yield of 19% (6/31 remaining families). In WES-negative families, the incremental cost per additional diagnosis using WGS following WES reanalysis was AU$36,710 (£19,407;US$23,727) and WGS alone was AU$41,916 (£22,159;US$27,093) compared to WES-reanalysis. When we simulated the use of WGS alone as an initial genomic test, the incremental cost for each additional diagnosis was AU$29,708 (£15,705;US$19,201) whereas contemporary WES followed by WGS was AU$36,710 (£19,407;US$23,727) compared to contemporary WES. Our findings confirm that WGS is the optimal genomic test choice for maximal diagnosis in Mendelian disorders. However, accepting a small reduction in diagnostic yield, WES with subsequent reanalysis confers the lowest costs. Whether WES or WGS is utilised will depend on clinical scenario and local resourcing and availability.

European Journal of Human Genetics (2022) 30:1121–1131; https://doi.org/10.1038/s41431-022-01162-2

INTRODUCTION

Genomic technologies have improved Mendelian disorder diagnosis, with whole genome sequencing (WGS) having the greatest diagnostic yield [1–3]. The higher cost of WGS sequencing and long-term data storage remain barriers to its routine implementation. Without public funding for genomic testing in most countries, diagnostic yields are balanced against budgetary limitations. The impact of coding variation on gene function identified through whole exome sequencing (WES) and WGS is well understood. The advantages of WGS for improving diagnostic yield are coding region coverage consistency, sequencing of newly-annotated coding regions, and improved detection sensitivity for structural variants (SVs), particularly copy number variants (CNVs) [2]. Interpreting genetic variation in non-coding regions identified primarily through WGS remains challenging, leading to a perceived lack of additional WGS utility compared to WES [4], however several reports have identified non-coding causes of Mendelian diseases [5–7].

While WGS increases the diagnostic yield over WES in Mendelian disorders, there are few studies exploring the degree
of improvement. Such studies would assist in selecting the optimal clinical genomic investigation. A small number of studies have assessed WGS diagnostic yields in WES-negative Mendelian disorder cohorts, with diagnostic rates between 7 to 34% [8–11]. The increased diagnostic rate in these studies was due to CNV detection, improved coverage of difficult to sequence regions, and identification of pathogenic variants in non-coding regions and mitochondrial DNA. In addition to clinical impact, economic evaluation of a new technology is important before seeking scarce funding for its routine implementation into standard care. Here, we performed WGS in a WES-negative Mendelian cohort to determine the extent that WGS increases the diagnostic yield over WES and impacts diagnostic costs.

SUBJECTS AND METHODS
Cohort ascertainment
Individuals (n = 91; 64 families) with undiagnosed suspected Mendelian disorders were recruited from genetics units in New South Wales (NSW), Australia, from 2013 to 2017. Affected individuals had undergone a range of diagnostic investigations such as chromosomal microarray (CMA) in those with intellectual disability (ID), and in some, targeted gene sequencing, but no WES or WGS prior to this study [12]. Original WES studies were performed at the Kinghorn Centre for Clinical Genomics (KCCG) and the NSW Health Pathology Randwick Genomics Laboratory (RGL), with one family sequenced at Radboud University Medical Centre Nijmegen (RUMC). 41% of the original KCCG and RGL WES cohort had diagnostic findings [12, 13]. Following completion of WES analysis, individuals who remained undiagnosed were recruited for WGS, resulting in 38 families with 59 affected individuals and 41 unaffected first-degree relatives.

Genomic sequencing and bioinformatics analysis
Original WES. WES was performed from 2013–17. RGL WES was performed on the Illumina HiSeq 2500 [12]. Family 12 had WES at RUMC on the SOLiD platform as described previously [14]. Accredited WES bioinformatics pipelines were utilised including GAIA at RGL [13], in-house methods at the RUMC, and Seave at KCCG [12]. CNV analysis was performed using Conifer [15] or XHMM [16].

WGS. DNA was extracted from EDTA blood or cultured fibroblasts (2 families). Sequencing was performed on probands and unaffected relatives between 2016–17 on Illumina HiSeq X instruments on libraries generated using either the KAPA Hyper PCR-free kit (36 families) or the TruSeq Nano DNA kit (2 families). Variants were called after hs37d5 reference human genome [12] alignment using a BWA/GATK best practices pipeline. Single nucleotide variants (SNVs) and small insertion/deletion (indel) variants were annotated using VEP, converted into GEMINI databases [17], and loaded into the web-based variant filtration platform, Seave [18]. Sample gender and relatedness quality checks were performed using KING (v1.4) [19] and PLINK (v1.90b1g) [20].

Homzygosity mapping was performed using ROHmer (Puttick et al., manuscript in preparation). Mitochondrial SNV/indel analysis used mity [21] which runs FreeBayes (unpublished data). SVs including CNVs were identified using ClinSV [22], combining discordantly-mapping read pairs, split-mapping reads, and depth of coverage changes. SVs were annotated with population allele frequencies derived from 500 healthy controls [23], the 1,000 Genomes Project [24], and for protein-coding gene overlap.

WGS variant prioritisation and interpretation
Nuclear SNVs and indels were filtered, prioritised, and interpreted by a clinical geneticist with genomic analysis expertise. Variants were discarded if the minor allele frequency was >2% (autosomal recessive (AR) or X-linked recessive inheritance) and >0.1% (autosomal dominant (AD)) in population databases. Restricting with a predicted low impact on protein function. WGS candidate variant pathogenicity assessment was made using in silico prediction tools (SIFT [25], PolyPhen2 [26], PROVEAN [27], CADD [28]), and aggregate pathogenicity scores from Varcarcs [29]. Mitochondrial variants were filtered to known disease variants or overlapping phenotypes in MITOMAP [30]. SVs and CNVs were filtered by rarity, genotype-phenotype overlap, and family segregation.

Variants with genotype-phenotype correlation were reviewed for sequence quality in the Integrative Genomics Viewer (IGV) [31]. Candidate variants were classified by genetic pathologists utilising the American College of Medical Genetics (ACMG/AMP) guidelines and subsequently validated by Sanger sequencing, including family segregation, and reported if likely pathogenic/pathologic [32].

WES retrospective reanalysis
Retrospective WES reanalysis was performed on original WES data approximately 2 years following original WES analysis to determine if WGS diagnoses could be identified using contemporary techniques. If WGS-diagnosed variants were absent from WES reanalysis, an assessment was made of WES coverage over the critical region and the variant presence in VCF files.

Health economic analysis
A health economic analysis was undertaken to understand the cost implications of genomic sequencing in Mendelian disorders. The incremental diagnostic and cost differences were analysed between the provision of WGS and WES for: (1) WES-negative individuals (38 families) and (2) individuals modelled as having had WES and WGS available with a contemporary analysis pipeline ab initio for the original 64 families (referred to as the simulated early genomic testing model).

1. Economic analysis for 38 WES-negative families. We calculated the incremental costs per additional WGS diagnosis when WES reanalysis was performed followed by WGS, and when only WGS was performed. As WES reanalysis on WES-negative cases is standard diagnostic care in the Australian healthcare system, WES reanalysis was the comparator for our analysis.

2. Economic analysis of the simulated early genomic testing model (64 families) Initial WES and WGS diagnostic rates were estimated using combined diagnoses from WES on the original cohort (64 families) and subsequently either contemporary WES reanalysis or WGS on the remaining 38 WES-negative families. We calculated the incremental costs per additional WGS diagnosis for contemporary WES followed by WGS and WGS alone, both compared to contemporary WES.

RESULTS
Cohort demographics
Proband ages ranged from newborn to 73 years, with half of paediatric age, more affected males (64%), and parental consanguinity in 18%. Twenty families had a single affected proband, most undergoing trio sequencing (17/20). Eighteen families had multiple affected probands, with most (14/18) undergoing WGS of two affected family members. Patient demographics are summarised in Supplementary Table 2. The average time between
original WES and WGS analysis was 1.8 years (SD ± 0.4) at KCCG, 2.4 years (SD ± 1.0) at RGL; combined 2.1 years (SD ± 0.7).

WGS diagnoses were made in one-third of WES-negative families

WGS-based analysis diagnosed 34% of the previously undiagnosed cohort with one diagnosis per family (13/38 families; Table 1). Diagnoses were made in well-characterised diseases genes and due to SNVs and indels in 12 families and a CNV in 1 family. The greatest proportion of diagnoses by disease categories were haematological (2/2 families), skeletal (2/3 families), and ID (8/24 families; non-syndromic ID 3/7, syndromic ID 5/17) (Supplementary Fig. 1).

WGS diagnoses were not detected through the original WES (Table 1, Fig. 1) due to a previously unknown gene-disease association (23%), insufficient sequencing coverage (31%), the variant prioritisation pipeline (15%), the bioinformatics pipeline (23%), or CNV detection (8%).

WGS had increased sensitivity for detecting structural variation

WGS data were evaluated to assess the impact of SVs on diagnostic yield. A 1.4 kb deletion encompassing part of exon 1 of RAB39B was identified in an X-linked ID family (Family 4, Table 1; Fig. 2A). The RAB39B deletion was validated in males using high-resolution CMA, adopting a lowered detection threshold of 4 probes from the standard 5 probes and a custom multiplex ligation-dependent probe amplification (MLPA). This deletion was missed on WES CNV analysis although visualisation of raw reads showed an absence of exon 1 coverage. A family with Opitz G/BBB syndrome had a WGS-detected SV of uncertain significance. Prior MID1 sequencing and WES were negative. There was evidence for two linked SV duplication events involving an intron of MID1 on chromosome X and a region on chromosome 1 involving SDF4 without a disease association. The X-linked pedigree is consistent with co-location of the duplications on chromosome X segregating with disease (Fig. 2B, C). Studies investigating the impact of the SV on MID1 are in progress.

Diagnoses made outside the standard variant analysis pipeline

Two diagnoses were made from bespoke analyses following initial negative routine variant prioritisation. Family 13 had a suspected X-linked or AD connective tissue disorder with features similar to Weill-Marchesani syndrome. Analysis for a shared candidate allele in an affected aunt and nephew was negative. Individual analyses were performed and, unexpectedly, a homozygous variant in ASPH (NM_004318.3:c.1695C > A; p.(Tyr565*)) associated with AR Traboulsi syndrome was identified in the aunt. This variant was present in the nephew in compound heterozygosity with a separate nonsense ASPH variant (NM_004318.3:c.1782G > A; p.(Trp594*)) associated with AR Traboulsi syndrome was identified in the aunt. This variant was present in the nephew in compound heterozygosity with a separate nonsense ASPH variant (NM_004318.3:c.1782G > A; p.(Trp594*)), demonstrating the presence of both homozygous and compound heterozygous ASPH alleles in the same family. Patient and pedigree review confirmed that their phenotype was consistent with Traboulsi syndrome, and that the aunt’s parents were third cousins. WES reanalysis confirmed that the family would have been diagnosed had this unusual mode of inheritance been considered.

Family 2 with AD macrothrombocytopenia (Table 1) underwent an extended analysis to assess low impact variants in platelet disorder genes. This identified a previously reported pathogenic variant in the 5′UTR of ANKRD26 (NM_014915.2:c.−116G > T) with a consistent haematological disease phenotype [33]. Sanger sequencing confirmed the variant segregated with disease. WES reanalysis did not identify this variant due to absent coverage of the 5′UTR in the earlier capture system. Improved coverage in a newer, alternate WES platform means this diagnosis would most likely have been made using current WES technology, provided variants of predicted low impact were prioritised through the pipeline (Supplementary Fig. 2).

WES reanalysis would have detected over half of the WGS diagnoses

WES reanalysis identified the diagnosis in 7/13 families where WGS provided a diagnosis (54%); total WES-negative cohort 7/38 families, 18%; Table 1; Fig. 3). Therefore, WGS provided an additional diagnostic yield following WES reanalysis of 19% of WES-negative families (6/31 remaining families). The majority of new WES diagnoses were due to improvements in the bioinformatics/variant filtering pipeline (4/7; Table 1: families 1, 6, 8, 9), followed by new disease gene identification (2/7; families 7, 11), and analysis outside the standard pipeline (1/7; family 13). In those that remained undiagnosed after WES reanalysis (6/13 families), insufficient coverage of the diagnostic variant was the main cause (4/6; Table 1: families 2, 3, 5, 12), and one missed CNV (family 4) and one bioinformatics pipeline error (family 10).

WGS versus WES as an initial genomic test

We estimated the diagnostic yield of WGS over a contemporary WES pipeline in the original cohort of 64 genomic-naïve families (Fig. 3). To do this, original WES diagnoses and additional diagnosed families from WGS or contemporary WES reanalysis were combined, assuming all original WES diagnoses would have been made with contemporary WES and WGS. From this analysis, a contemporary WES pipeline would have yielded a 52% diagnostic yield (33/64 families: 26 original WES families and 7 additional from contemporary WES pipeline). Had WGS been performed at the outset, 61% of families would have been diagnosed (39/64 families; 26 original WES, 13 additional WGS), resulting in an additional 9% yield over contemporary WES, unique to WGS.

Health economic analysis

Economic analysis for WES-negative families. The incremental cost per additional WGS diagnosis following WES reanalysis was AU$36,710 (£19,407; US$23,727) (95% CI: AU$20,607; $112,902) compared to WES reanalysis alone. For WGS alone, the incremental cost per additional diagnosis was AU$41,916 (£22,159; US$27,093) (95% CI: AU$22,790; $128,107) compared to WES reanalysis alone. This pathway conferred the greatest costs with the same diagnostic rate as the WES reanalysis followed by WGS pathway.

Economic analysis for the simulated early genomic testing model. WGS following initial WES (Table 2, ii): for each additional (incremental) WGS diagnosis over initial WES, the cost would be AU$36,710 (£19,407; US$23,727) (95% CI: AU$20,607; $112,902). Initial WGS (Table 2, iii): for each incremental initial WGS diagnosis, there would be an additional cost of AU$29,708 (£15,705; US$19,201) (95% CI: AU$16,612; $90,195) compared to initial WES. Thus, of the two WGS options, WGS as the initial test was the best value for money, producing the same diagnoses at a lower cost than WGS following WES.

Sensitivity analysis. There were substantial differences in genomic sequencing costs between laboratories, with more widely divergent WGS costs. Trio WGS costs ranged from AU$7,557 (£3,995; US$4,884) (VCGS laboratory) to AU$11,446 (£6,051; US$7,398) (Centogene laboratory), and trio WES ranged from AU$3,713 (£1,963; US$2,400) (PerkinElmer laboratory) to AU$4,345 (£2,297; US$2,808) (Centogene laboratory). Accordingly, we undertook a sensitivity analysis to determine what impacts the use of higher or lower WES and WGS costs may have on the results.

Economic analysis for WES-negative families: The incremental cost per additional WGS diagnosis following WES reanalysis
Table 1. WGS diagnoses, WES reanalysis diagnoses, and reasons why WES diagnoses missed.

| F | Pt. | Phenoype | WGS diagnosis | ACMG variant classification | Disorder | Original WES approach | WGS approach | Why missed on original WES | Retrospective contemporary WES reanalysis | WES coverage |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1.2 | Hermatological | Oculocutanous albinism, absent platelet dense granules, ddx Hermansky-Pudlak syndrome; parental consanguinity for both probands | NC_000101.11:g.102066504G>T (GRCh38); NM_024734.5c.1030G>T; NM_079023.2p.Glu344Ter) SCV00189937 | Pathogenic: PVS1, PM1, PM2, PM3, supporting | Hermansky-Pudlak syndrome | Affected grandmother & grandson | Affected grandmother & grandson | Bioinformatics pipeline | Diagnosed. Updated bioinformatics pipeline. |
| 2 | 3,4,5 | Hermatological | Macrothrombocytopenia, platelet count 30-40 x 10^9/L; abnormal platelet function & bleeding disorder. | NC_000101.11:g.21700442G>A (GRCh38); NM_014915.2c.116G>T; exon 1 of 34 (SUTR) position 57 of 414 | Likely Pathogenic: RCV000851960.1 | Thrombocytopenia 2 | 3 affected individuals (cousins & uncle) & 1 unaffected (sibling) | 3 UTR not covered | Undiagnosed. No coverage of 5' UTR | Genomic location covered |
| 3 | 6,7,8 | NS-ID | ID, epilepsy; consanguinity | NC_000101.11:g.50249414T>C (GRCh38); NM_001004127.2c.1184T>C | Likely Pathogenic: PM1, PM2, PM3, supporting, PP3 | Congenital disorder of glycosylation type 1p (MM 613661) | Sibling pair | Affected sibling pair, aunt & unaffected parents | Reduced coverage | Undiagnosed. Reduced coverage. | Genomic location covered |
| 4 | 9,10 | NS-ID | ID, additional phenotype Dec 2017!Parson's diagnosis, increased tremors, epilepsy, peripheral neuralgia, scoliosis/cerebral brain iron accumulation, N/C | NC_000231.11:g.155264167, 155265545del (GRCh38); Partial exon 1 deletion | Pathogenic | X-linked mental retardation; WSiam syndrome (MM 300277; 311510) | Sibling pair | Sibling pair | CNV caller may have missed due to issues with exon 1 calling | Undiagnosed. Not identified through CNV analysis. |
| 5 | 11,12 | NS-ID | Severe ID, absent speech, hypotonia microcephaly. N/C | NC_000231.11:g.15854687C>T (GRCh38); NM_001272071.2c.1-1>G; A (p.) | Likely Pathogenic: PVS1, PM2 | Mental retardation, X-linked syndromic retardation (MM 304340) | Sibling pair | Sibling pair | Reduced coverage | Undiagnosed. Reduced coverage. | Reduced coverage of genomic location |
| 6 | 13 | S-ID | Severe ID, no speech, dysmorphic features: thick hair, epicanthic folds, mildly dysplastic helices, keratosis pilaris, dermatoglyphia pes planus, slender fingers & toes, flat nail beds, mild contractures of elbows & knees, mild obesity. N/C | NC_000231.11:g.11765731T>A (GRCh38); chrX:g.11783850 T>A; NM_078629.3c.1171 = 2T>A | Pathogenic: PS1, PS2, PS3, PM2, PM3, PM2, PM3 | Pathogenic: PS1, PS2, PS3, PM2, PM3, PM2, PM3 | Trio | Trio | Bioinformatics pipeline | Diagnosed. Updated bioinformatics pipeline. |
| 7 | 14 | S-ID | Moderate ID, adducted thumbs, hypotonia, abnormal aortic valve & prominent aortic root. N/C | NC_000231.11:g.71337917G>A (GRCh38); NM_181672.2c.307G>A; NM_004595.4c.152A>G; NM_004586.2p.(Thr315Glu); Large Grantham 194 SCV00189942 | Likely Pathogenic: PM1, PM2, PP2, PP3, PM4, supporting (RCV00024463.1) | X-linked mental retardation (MM 300997) | Trio | Trio | Unknown disease gene association | Diagnosed. Interim disease gene publication. |
| 8 | 15,16 | S-ID | ID, dysmorphic, epilepsy, osteoporosis and fractures (one proband). N/C | NC_000231.11:g.21967298A>G (GRCh38); NM_004595.4c.152A>G; NM_004586.2p.(Thr315Glu); Large Grantham 194 SCV00189942 | Likely pathogenic: PM2, PS4, moderate | Snyder-Robinson syndrome (MM 309583) | Sibling pair | Sibling pair | Variant prioritization pipeline; stringent pathogenicity filter applied (CADD > 15) | Diagnosed. Updated variant prioritization pipeline. |
| 9 | 17 | S-ID | Severe ID, hypotonia, hypermobility, constipation, macrocephaly, prominent forehead, long face, slender hands & feet, prominent foetal finger pads, kyphoscoliosis, muscle wasting without significant weakness. N/C | NC_00019.10:g.13025339C>T (GRCh38); NM_001271043.2c.370C>T; NM_001257972.1p.(Arg124Trp) SCV00189944 | Pathogenic: PS2, PM1, PM2, PM5, PM4, moderate, PP2, PP3, PS4 | Sotos type 2 (MM 614753) | Trio | Trio | Bioinformatics pipeline; unlisted parental zygosity at genomic location | Diagnosed. Updated bioinformatics pipeline. |
| F | Pt. | Phenotype | System | Description | Gene / Inheritance | Disease-causing variant | ACMG variant classification | Disorder | Original WES approach | WGS approach | Why missed on original WES | Retrospective contemporary WES reanalysis | WES coverage | ES analysis/reanalysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 18 | S-ID | FGF2R2 | AD de novo | NC_000010.11:g.121515280 T > C (GRCh38); NM_000141.4:c.1124 A > G; NP_000132.3:p.(Tyr375Cys) | SCV001809945 | Recurrent Pathogenic | RCV000762799 | Beare-Stevenson syndrome (extended FGFR2 spectrum; MIM: 123790) | Trio | Trio | Bioinformatics pipeline | Undiagnosed. Variant calling failure in bioinformatics pipeline. |
| 11 | 19, 20 | Neurological | MPEP | AR, comp het | (1) NC_000013.11:g.23837561 G > C (GRCh38); NM_005932.3:c.1534 C > G; NP_005923.2:p.(His512Asp); SCV001809946 | Exon 1 donor canonical site | Pathogenic: PVS1, PM2, PP1_strong | Craniosynostosis (MIM: 600775) | Multiple affected individuals | Singleton | Reduced coverage | Undiagnosed. | Diagnosis outside standard pipeline. |
| 12 | 21 | Skeletal | ASPH | AD | Patient 22: NC_000008.11:g.61548140G > T (GRCh38); NM_004318.3:c.1095C > A; NP_004309.2:p.(Ty565Ter); Patient 23: 1st variant and NC_000008.11:g.61256095 C > T (GRCh38); NM_004318.3:c.1705G > A; NP_004309.2:p.(Trp594Ter) | SCV001809948 | (1) Pathogenic; PVS1, PM2, PM3, supporting (2) Pathogenic; PVS1, PM2, PM3 | Traboulsi syndrome (MIM: 601552) | Multiple affected individuals | Multiple affected individuals | Variant prioritization pipeline; inheritance pattern assumption | Diagnosed. Analysis outside standard pipeline. |

AD: autosomal dominant, ADHD: attention deficit hyperactivity disorder, AR: autosomal recessive, CMA: chromosome microarray, comp het: compound heterozygous, F: family, hom: homozygous, L: litre, N/C: non-consanguineous, NS-ID: non-syndromic intellectual disability, Pt: patient, S-ID: syndromic intellectual disability, SCV: submitted record in ClinVar/accession number, USS: ultrasound scan, WES: whole exome sequencing, WGS: whole genome sequencing, XLR: X-linked recessive.
ranged from AU$36,659 (£19,380; US$23,693) (lowest WGS cost) to AU$53,307 (£28,181; US$34,453) (highest WGS cost) when compared to WES reanalysis alone, with the cost of WES reanalysis unchanged. The sensitivity analysis showed that the conclusions for WES-negative families would not be altered by lower or higher genomic costs.

Economic analysis for the simulated early genomic testing model: One-way sensitivity analysis of the incremental cost for each additional initial WGS diagnosis compared to initial WES was performed for a range of available WES and WGS costs (Supplementary Fig. 3). The result is more sensitive to WGS costs, with the incremental cost ranging from AU$28,262 (£14,941; US $18,266) to AU$60,681 (£32,079; US$39,219) per additional WGS diagnosis, primarily driven by the wider range of commercially available costs for WGS compared to WES.

**DISCUSSION**

In this Mendelian disorder cohort, WGS resulted in a diagnosis in one third (34%; 13/38 families) of undiagnosed families who had previously had WES. However, when controlling for factors such as improvements to gene-disease knowledge and genomic pipelines through contemporary WES reanalysis, the WGS diagnostic yield reduced to 19% (6/31 remaining families). If WGS was applied as an initial test to our original cohort of 64 undiagnosed Mendelian families, the increased diagnostic yield unique to WGS was 9% relative to contemporary WES. The majority of the WGS diagnostic
gains (4/6 diagnoses; Fig. 1C) were due to reduced WES coverage of critical regions that may be solved through an improved WES platform. Inspection of sequencing coverage in unrelated individuals using the newer Illumina NovaSeq 6000 ES Agilent CREv2 showed adequate coverage for variant identification in 3 of the 4 missed WES diagnoses (Supplementary Fig. 4). Although there was a low detection rate of pathogenic SVs in this study, this may increase with time as more clinically important SVs are characterised and thus influence WGS diagnostic yields over WES [34, 35].

Solving the undiagnosed
Understanding why genomic diagnoses are missed can lead to alterations to genomic pipelines and improved Mendelian disorder diagnosis. A WGS diagnosis in a deceased foetus with suspected Raine syndrome followed multiple sequential non-informative investigations including prenatal CMA, FAM20C sequencing and MLPA, a craniosynostosis panel, and WES. On WGS, a de novo pathogenic FGFR2 variant (p.Y375C) was identified, diagnosing Beare-Stevenson syndrome, conferring a greatly reduced reproductive recurrence risk compared to the suspected AR disorder. The craniosynostosis panel had included FGFR2, but not the critical exon, and the missed WES diagnosis was due to a failure of the variant caller despite good sequencing coverage, which has been subsequently addressed.

Generic genomic filtering pipelines may rely on assumptions about inheritance patterns or predicted protein impacts. Failure to identify a molecular aetiology after a familial analysis should prompt consideration of an alternative analytical method, such as singleton proband analysis in the family with Traboulsi syndrome. Similarly, incorporating known Mendelian disorder disease-causing variants from ClinVar that are bioinformatically predicted to be of low impact, improves variant detection. Accessing specialist gene-disease knowledge will be important for recognition of such variation.

WES reanalysis remains valuable in increasing diagnostic yields in unsolved cases, with an additional diagnostic rate of 11% (7 of 64 families) made over an approximate 2-year period [12]. However, reanalysis of WES obtained from older platforms may be ineffective in some unsolved individuals due to overall reduced sequencing coverage compared to contemporary platforms. There remains a diagnostic gap with WES for smaller SVs that is best approached through non-WES methodologies such as exon-level arrays or WGS. While contemporary WES coverage has improved, including slightly expanded coverage of non-coding regions containing pathogenic variation [5, 6, 36], WGS enables the unbiased detection of non-coding variants without the limitation of target enrichment based on potentially outdated gene annotations. Although less is understood how non-coding region variation impacts biological function, there are numerous examples of deep intronic variation affecting gene splicing [7] and other pathogenic non-coding variants [5, 6] such as the 5’ UTR ANKRD26 variant in this study. Proof of causation for novel non-coding variation is challenging but higher throughput methodologies for functional studies may lower costs and improve understanding of such variation, making diagnostic reporting more feasible and increasing the importance of WGS [37]. While we have compared current diagnostic WES and WGS pipelines, there are a number of techniques such as improved splicing prediction tools [38] and RNAseq [36] that are not yet routinely available but have potential to further increase diagnostic rates over current WES and WGS.
Table 2. Economic comparative analysis of WGS with WES and WES reanalysis.

|                               | Unresolved Mendelian families from original WES analysis (n = 38 families) | WGS versus WES as initial genomic test (n = 64 families; includes 38 WES-negative families) |
|-------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
|                               | Contemporary WES reanalysis on WES-negative cases (a)                     | Contemporary WES reanalysis followed by WGS* (b)                                       |
| Diagnoses with WES reanalysis | 7                                                                         | 7 (7/38; 18%)                                                                             |
| Diagnoses with contemporary WES| —                                                                         | —                                                                                         |
| Diagnoses with WGS           | —                                                                         | 33 (33/64; 52%)                                                                          |
| Total diagnosed              | 7 (7/38; 18%)                                                             | 13 (13/38; 34%)                                                                           |
| Total cost of WES reanalysis | AU$15,727 (£8,314; US$10,164)                                             | AU$15,727 (£8,314; US$10,164)                                                             |
| Total cost of contemporary WES| —                                                                         | —                                                                                         |
| Total cost of WGS            | —                                                                         | AU$220,268 (£116,445; US$142,362)                                                          |
| Total cost                   | AU$15,727 (£8,314; US$10,164)                                             | AU$267,240 (£141,277; US$172,722)                                                         |
| Incremental cost per additional WGS diagnosis |                                           |                                             |
| - Compared to WES reanalysis | Reference AU$36,710 (£19,407; US$23,727)                                    | AU$41916 (£22,159; US$27,093)                                                            |
| (95% confidence interval)    | (AU$20,607; 112,902)                                                     | (AU$22,790; 128,107)                                                                     |
| - Compared to initial WES    | Reference AU$36,710 (£19,407; US$23,727)                                    | AU$29,708 (£15,705; US$19,201)                                                           |
| (95% confidence interval)    | (AU$20,946; 112,942)                                                     | (AU$16,612; 90,195)                                                                      |

38 WES-negative unsolved Mendelian families are presented on the left, showing comparative costs for three alternative approaches to further genomic analysis: (a) contemporary WES reanalysis, (b) contemporary WES reanalysis followed by WGS, (c) WGS only. Original 64 unsolved Mendelian families are presented on the right with a simulated early genomic testing model. Comparative costs are shown for three initial genomic approaches: (i) WES (contemporary), (ii) WES followed by WGS, (iii) WGS only. The number of diagnosed families from each technology are shown as well as the total costs and the incremental cost for each additional WGS diagnosis. Costs are in Australian Dollars (laboratory costs obtained as of 13th May 2020 and conversion to British Pounds, and US Dollars with a rate of 1 AUD = 0.53 GBP/0.65 USD/0.60 EUR (https://www.xe.com/currencytables/?from=AUD&date=2020-05-13#table-section)).

*Includes cost of WES reanalysis and no WGS cost for families diagnosed through ES reanalysis.

It was assumed that all cases diagnosed with WES would have been diagnosed with WGS.
WES or WGS as an initial genomic diagnostic test?

Variants assessed for disease diagnosis are almost exclusively in coding regions and so it has been argued that a well performed contemporary WES study is a cost-effective screen and the best first-line methodology [12, 39]. However, we may be moving towards a time when WGS will be adopted as a first-line test [40]. The main limitation of WES is a lower sensitivity for detecting structural variation, particularly complex variation [39]. Further, when considering the maximum diagnostic yield alone, this study and others have shown that WGS boosts the diagnostic yield in WES-negative Mendelian disorder cohorts [8–11]. The magnitude of this diagnostic increase depends on the modernity of the WES approach relating to exome enrichment, analytic pipelines, and the likelihood of CNVs or the presence of an unusual genomic mechanism. There is evidence that small CNVs may be more important in Mendelian disease diagnosis than previously recognised [35] so the increased sensitivity of WGS for CNV detection is advantageous. The combination of WES with newer technological platforms such as long-read sequencing could result in an increased diagnostic sensitivity for CNVs without the higher costs of performing WGS.

Decisions about when to use WES and WGS remain important because there is a trade-off between the lower cost of WES and the higher diagnostic yield of WGS. To date, there have been few studies on comparing the relative costs of WGS with WES or after WES reanalysis [41]. The economic analyses in this study show that the economic decision whether to use WES or WGS in part depends upon whether prior genomic testing has occurred. If additional diagnoses are sought when WES has been performed previously, the lowest cost use of resources is to perform WES reanalysis. However, to achieve maximal diagnoses, the most cost-effective strategy is to perform WGS after WES reanalysis, with an incremental cost per additional WGS diagnosis of AU$36,710 (£19,407; US$23,727) in this study. This strategy incurs a lower cost than performing WGS after original WES without WES reanalysis, with the same diagnostic yield.

For people who have not had genomic testing, the most cost-effective strategy for maximal diagnoses is to perform initial WGS, with an incremental cost of AU$29,708 (£15,705; US$19,201) per WGS diagnosis. However, acknowledging that some diagnoses will be missed and that not all jurisdictions have access to the required resources for WGS, the lowest cost pathways are to perform WES reanalysis in WES-negative individuals and initial WES in people who have not had genomic testing. It is important to note that the cost differences between WES and WGS may be specific to this study cohort and that there is no universally acknowledged willingness-to-pay-threshold for a diagnosis [42]. Further, the additional expenditure for each WGS diagnosis achieved may still result in downstream health and social cost savings, which, over a lifetime, may dwarf the costs of WGS [43].

The implications of diagnoses for families on quality of life outcomes, management change, access to reproductive technologies, eligibility for services, access to support groups and the impact on both health and social costs all need to be considered when allocating scarce resources. The economic analysis in this study lacks information about such outcomes that would provide information on quality adjusted life years (QALYs) and allow for a cost utility analysis. Further, we have not calculated the costs of additional investigations that may be incurred following a negative WES result compared to WGS. However, the economic analysis does provide important information about the financial resource implications of implementing WES and WGS, when considering these test costs alone.

In addition to balancing test cost and maximising diagnoses, the clinical scenario also influences genomic test choice. In settings where there is a high chance of intervention if a genomic diagnosis is made, it can be argued that WGS, with the maximal chance of diagnosis, should be chosen. Such scenarios may include the acutely unwell children in the neonatal or paediatric intensive care units (NICU/PICU) [44], or for urgent reproductive situations such as an at-risk pregnancy. However, such decisions are not made in isolation, with availability and resourcing impacting the option to provide, or choice of genomic testing, even in urgent clinical scenarios.

WGS is the optimal genomic test choice to maximise the diagnostic rate in Mendelian disorders across all clinical scenarios. However, accepting a small reduction in diagnostic yield, WES with reanalysis confers the lowest costs. Whether WES or WGS is utilised will depend on the clinical scenario and local resourcing and availability.

DATA AVAILABILITY

Web-based variant filtration platform, Seave, software is available (https://github.com/KCCG/seave). Causative variants have been deposited to the ClinVar database (SUB10158418).

REFERENCES

1. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BW, Willemsen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511:344–7.
2. Belkadi A, Bolze A, Ian Y, Cobat A, Vincent QB, Antipenko A, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci. 2015;112:5473–8.
3. Stavroupolous DJ, Merico D, Jobling R, Bowdin S, Monfared N, Thiruvahindrapuram B, et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPG Genom Med. 2016;1:15012.
4. Harel T, Lupski JR. Genomic disorders 20 years on-mechanisms for clinical manifestations. Clin Genet. 2018;93:439–49.
5. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009;136:777–93.
6. Lettice LA, Hill AE, Devenney PS, Hill RE. Point mutations in a distant sonic hedgehog cis-regulator generate a variable regulatory output responsible for preaxial polydactyly. Hum Mol Genet. 2008;17:978–85.
7. Bagnall RD, Ingles J, Dinger ME, Cowley MJ, Ross SB, Minoche AE, et al. Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;72:419–29.
8. Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015;47:717–26.
9. Alfares A, Aloraini T, subaie LA, Alissa A, Qudsi AA, Alahmad A, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. Genet Med. 2018;20:1328–33.
10. Lionel AC, Costain G, Monfared N, Walker S, Feustler MT, Hosseinmi SM, et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med. 2018;20:435–43.
11. Helman G, Lajoie BR, Crawford J, Takanoasho A, Walkiewicz M, Dolzenko E, et al. Genome sequencing in persistently unsolved white matter disorders. Ann Clin Neurol. 2020;7:144–52.
12. Ewans LJ, Schofield D, Shrestha R, Zhu Y, Gayevskiy V, Ying K, et al. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. Genet Med [Internet]. 2018 Mar [cited 2018 May 18]; Available from: http://www.nature.com/doifinder/10.1038/gim.2018.39.
13. Sundarcombe SL, Berbic M, Evans CA, Cliffe C, Elkis G, Temple SEL, et al. Clinically responsive genomic analysis pipelines. J Mol Diagn. 2021;23:894–905.
14. Gilissen C, Arts HH, Hoischen A, Spruijt L, Mans DA, Arts P, et al. Exome sequencing identifies WDR5 variants involved in sensorinebrenner syndrome. Am J Hum Genet. 2010;87:418–23.
15. Krumm N, Sudmant PH, Ko A, O’Roak BJ, Malig M, Coe BP, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012;22:1525–32.
16. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet. 2012;91:597–607.
17. Paia U, Chapman BA, Kirchner R, Quinlan AR GEMINI: Integrative Exploration of Genetic Variation and Genome Annotations. Gardner PP, editor. PLoS Comput Biol. 2013;9:e1003153.
18. Gayevskiy V, Roscioli T, Dinger ME, Cowley MJ Seave: a comprehensive web platform for storing and interrogating human genomic variation. Wren J, editor. Bioinformatics. 2019;35:122–5.
19. Manichekul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. Bioinformatics 2010;26:2867–73.

20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.

21. Flicek P, Livak KJ, Dunning M,de Koning D, Ritchie S, Duley J, et al. Enhancing the UCSC Genome Browser annotation pipeline: whole-genome sequencing data. Genome Med. 2021;13:32.

22. Minoche AE, Lundie B, Peters GB, Ohnhorst T, Pines M, Thomas DM, et al. ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Med. 2021;13:32.

23. Pines M, Lacaze P, Rath EM, Stone A, Brion MJ, Amour A, et al. The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nat Commun. 2020;11:435.

24. The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 2015;526:68–74.

25. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–81.

26. Adzhubei I, Schmidt S, Peshkin L, Ramensky V, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.

27. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 2015;31:2745–7.

28. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.

29. Li J, Shi L, Zhang K, Zhang Y, Hu S, Zhao T, et al. VarCards: an integrated genetic and clinical database for coding variants in the human genome. Nucleic Acids Res. 2018;46:D1039–48.

30. Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, et al. mtDNA Variation and Analysis Using Mitomap and Mitomaster: mtDNA Variation and Analysis Using Mitomap and Mitomaster. In: Bateman A, Pearson WR, Stein LD, Stormo GD, Yates JR, editors. Current Protocols in Bioinformatics [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2013 [cited 2019 Mar 21]. p. 1.23.1–
1.23.26. Available from: https://doi.org/10.1002/0471250953.b0112344.

31. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178–92.

32. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–23.

33. Pippucci T, Savoia A, Perrotta S, Pijou-Moix N, Noris P, Castegnaro G, et al. Mutations in the 5’ UTR of ANKR2D6, the Ankin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, TH2C. Am J Hum Genet. 2011;88:115–20.

34. Clarke J, Stark Z, Farnese L, Tan TY, White SM, Dimmock D, et al. Meta-analysis of the diagnostic and clinical utility of exome and sequence exome and chromosomal microarray in children with suspected genetic diseases. NJP Genom Med. 2018;3:16.

35. Truty R, Paul J, Kennemer M, Lincoln SE, Oliveses E, Nussbaum RL, et al. Prevalence and properties of intragenic copy-number variation in Mendelian disease genes. Genet Med. 2019;21:114–23.

36. Kremet I, Badar DM, Mertes C, Kopatch J, Pichler G, Iuso A, et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun. 2017;8:15824.

37. Starita LM, Ahituv N, Dunham MJ, Kitzman JO, Roth FP, Seelig G, et al. Variant interpretation: functional assays to the rescue. Am J Hum Genet. 2010;1:315–25.

38. Jaganath K, Frizas K, Karzisopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li Y, et al. Predicting splicing from primary sequence with deep learning. Cell 2019;176:535–548.e24.

39. Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21:2413–21.

40. Marshall CR, Bick D, Belmont JW, Taylor SL, Ashley E, Dimmock D, et al. The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. Genome Med. 2020;12:48.

41. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:1122–30.

42. Sagoo GS, Nobury G, Mohammed S, Kroese M. A health economic evaluation. 2017;17:33.

43. Doble B, Schofield D, Evans CA, Groza T, Mattick JS, Field M, et al. Impacts of genomics on the health and social care of people with intellectual disability. J Med Genet. 2020 Jan;56:1064–5.

44. Petrikin JE, Cakici JA, Clark MM, Willing LK, Sweeney NM, Farrow EG, et al. The NSIGHT1 randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants. NJP Genom Med. 2018;3:6.

ACKNOWLEDGEMENTS

We thank the patients, their families, and physicians for their participation in this study. We thank the Kinghorn Centre for Clinical Genomics for assistance with production and processing of genome sequencing data.

AUTHOR CONTRIBUTIONS

LJE—Grant funding chief investigator, WGS data analysis, ES retrospective data analysis at KCGG/Garvan, manuscript primary author. AEM—WGS structural variant (SV) tool development and data generation and assistance with SV interpretation, assistance with WGS data bioinformatics. DS—Grant funding chief investigator, economic analysis of average and incremental cost of WGS diagnoses, drafting of manuscript. RS—Economic analysis of average and incremental cost of WGS diagnoses, drafting of manuscript. CP—WGS mitochondial and homogygosity data generation and assistance with their interpretation. YZ—CNV data generation for exome sequencing from NSW Health Pathology Randwick, assistance with retrospective ES data generation for analysis. AD—WGS cohort quality checks, manuscript figure generation, linkage analysis. VG—WGS Seave bioinformatics and tool development, generation of databases. GE—Supervision within molecular laboratory within NSW Health Pathology Randwick. CW—Supervision within molecular laboratory within NSW Health Pathology Randwick. LA—Contribution of clinical cases including phenotype data. AC—Contribution of clinical cases including phenotype data. CAE—ClinSV repository assistance. CE—Contribution of clinical cases including phenotype data. M-LF—Contribution of clinical cases including phenotype data. LG—Contribution of clinical cases including phenotype data. AH—Contribution of clinical cases including phenotype data. BRK—Contribution of clinical cases including phenotype data. EPK—Contribution of clinical cases including phenotype data. ML—Contribution of clinical cases including phenotype data. DM—Contribution of clinical cases including phenotype data. EP—Contribution of clinical cases including phenotype data. SR—Contribution of clinical cases including phenotype data. AR—Contribution of clinical cases including phenotype data. RS—Contribution of clinical cases including phenotype data. WS—Contribution of clinical cases including phenotype data. AT—Contribution of clinical cases including phenotype data. MW—Contribution of clinical cases including phenotype data. MCK—Contribution of clinical cases including phenotype data; Sanger validation of ANKR2D6 variants. MF—Grant funding chief investigator, supervision of NSW Health Pathology Randwick laboratory where original exomes performed and Sanger segregation confirmation of molecular diagnoses, supervision of and writing of clinical pathologic diagnostic reports. MJC—Grant funding chief investigator, supervision and development of WGS tools Seave, ClinSV, mity, ROHmeer, methodology input, drafting of manuscript. MED—Grant funding chief investigator, supervision of KCGG/Garvan and first author work with primary direction of analysis, drafting of manuscripts.

FUNDING

Genome sequencing was funded through a grant from the NSW Office of Health and Medical Research. LJE was supported through an Australian Government Research Training Program Scholarship. MJC was supported by Cancer Institute NSW (13/ECF/1-46) and NSW Health Early-Mid career fellowship. TR was supported by the Australian NHMRC (APP1117394; APP1045465) and an International Biomedical Fellowship (512123). Open Access funding enabled and organized by CAUL and its Member Institutions.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

Informed consent was obtained for study participants. Study approval was granted by the Prince of Wales Hospital ethics committee, Australia (ref 13/094 and LNR/13/ SCHN/112).
ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41431-022-01162-2.

Correspondence and requests for materials should be addressed to Lisa J. Ewans, Marcel E. Dinger or Tony Roscioli.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/

© Crown 2022